Preventative treatment may be on the near horizon for those in the bleeding disorder community with FVIId and GT. Hemab Therapeutics is developing new preventative treatments for people with rare bleeding and clotting disorders. Many people with these disorders have limited options beyond blood transfusions and emergency care. Hemab is leveraging cutting-edge science to introduce prophylactic therapies that can help patients form healthy blood clots. Hemab’s goal is to ensure no patient with a blood clotting disorder is ever left without effective, proactive care.
The first asset aims to serve FVIId and GT:
Hemab is targeting 5 clinical assets by 2025 that aim to assist those in these communities:
Glanzmann Thrombasthenia, Factor VII Deficiency, Hemophilia B with inhibitors, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and others. Learn more about Hemab Therapeutics below:
https://hemab.com